3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Sell
33
SKHCF Quote, Financials, Valuation and Earnings
Last price:
$16.75
Seasonality move
:
-0.66%
Day range:
$16.75 - $18.10
52-week range:
$15.25 - $21.89
Dividend yield:
4.19%
P/E ratio:
22.75x
P/S ratio:
1.36x
P/B ratio:
1.52x
Volume:
12.9K
Avg. volume:
3.3K
1-year change:
-21.4%
Market cap:
$8B
Revenue:
$5.9B
EPS (TTM):
$0.70
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SKHCF
Sonic Healthcare
|
-- | -- | -- | -- | -- |
|
ATHE
Alterity Therapeutics
|
-- | -- | -- | -- | $9.00 |
|
IMMP
Immutep
|
-- | -- | -- | -- | -- |
|
KZIA
Kazia Therapeutics
|
-- | -- | -- | -- | -- |
|
MESO
Mesoblast
|
$2.1M | -- | -100% | -- | $11.00 |
|
OPT
Opthea
|
-- | -- | -- | -- | $11.80 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SKHCF
Sonic Healthcare
|
$16.75 | -- | $8B | 22.75x | $0.42 | 4.19% | 1.36x |
|
ATHE
Alterity Therapeutics
|
$3.99 | $9.00 | $34.9M | -- | $0.00 | 0% | 1.50x |
|
IMMP
Immutep
|
$2.14 | -- | $311.3M | -- | $0.00 | 0% | -- |
|
KZIA
Kazia Therapeutics
|
$1.80 | -- | $7.8M | -- | $0.00 | 0% | -- |
|
MESO
Mesoblast
|
$18.96 | $11.00 | $2.2B | -- | $0.00 | 0% | 196.60x |
|
OPT
Opthea
|
$3.69 | $11.80 | $567.8M | -- | $0.00 | 0% | 2,361.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SKHCF
Sonic Healthcare
|
27.4% | 0.543 | 22.58% | 0.86x |
|
ATHE
Alterity Therapeutics
|
-- | -4.982 | -- | -- |
|
IMMP
Immutep
|
-- | -0.152 | -- | -- |
|
KZIA
Kazia Therapeutics
|
-6.76% | 0.052 | 5.57% | 0.07x |
|
MESO
Mesoblast
|
-- | -0.629 | -- | -- |
|
OPT
Opthea
|
215.31% | 0.522 | 53.76% | 2.88x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SKHCF
Sonic Healthcare
|
-- | -- | 4.6% | 6.28% | -- | -- |
|
ATHE
Alterity Therapeutics
|
-- | -- | -- | -- | -- | -- |
|
IMMP
Immutep
|
-- | -- | -- | -- | -- | -- |
|
KZIA
Kazia Therapeutics
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
MESO
Mesoblast
|
-- | -- | -- | -- | -- | -- |
|
OPT
Opthea
|
-- | -- | -669.85% | -- | -- | -- |
Sonic Healthcare vs. Competitors
-
Which has Higher Returns SKHCF or ATHE?
Alterity Therapeutics has a net margin of -- compared to Sonic Healthcare's net margin of --. Sonic Healthcare's return on equity of 6.28% beat Alterity Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SKHCFSonic Healthcare-- -- $7.4B ATHEAlterity Therapeutics-- -- -- -
What do Analysts Say About SKHCF or ATHE?
Sonic Healthcare has a consensus price target of --, signalling downside risk potential of --. On the other hand Alterity Therapeutics has an analysts' consensus of $9.00 which suggests that it could grow by 125.56%. Given that Alterity Therapeutics has higher upside potential than Sonic Healthcare, analysts believe Alterity Therapeutics is more attractive than Sonic Healthcare.
Company Buy Ratings Hold Ratings Sell Ratings SKHCFSonic Healthcare0 0 0 ATHEAlterity Therapeutics1 0 0 -
Is SKHCF or ATHE More Risky?
Sonic Healthcare has a beta of 1.133, which suggesting that the stock is 13.342% more volatile than S&P 500. In comparison Alterity Therapeutics has a beta of 0.655, suggesting its less volatile than the S&P 500 by 34.451%.
-
Which is a Better Dividend Stock SKHCF or ATHE?
Sonic Healthcare has a quarterly dividend of $0.42 per share corresponding to a yield of 4.19%. Alterity Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sonic Healthcare pays 109.44% of its earnings as a dividend. Alterity Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SKHCF or ATHE?
Sonic Healthcare quarterly revenues are --, which are smaller than Alterity Therapeutics quarterly revenues of --. Sonic Healthcare's net income of -- is lower than Alterity Therapeutics's net income of --. Notably, Sonic Healthcare's price-to-earnings ratio is 22.75x while Alterity Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sonic Healthcare is 1.36x versus 1.50x for Alterity Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SKHCFSonic Healthcare1.36x 22.75x -- -- ATHEAlterity Therapeutics1.50x -- -- --
-
Which has Higher Returns SKHCF or IMMP?
Immutep has a net margin of -- compared to Sonic Healthcare's net margin of --. Sonic Healthcare's return on equity of 6.28% beat Immutep's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SKHCFSonic Healthcare-- -- $7.4B IMMPImmutep-- -- -- -
What do Analysts Say About SKHCF or IMMP?
Sonic Healthcare has a consensus price target of --, signalling downside risk potential of --. On the other hand Immutep has an analysts' consensus of -- which suggests that it could grow by 343.93%. Given that Immutep has higher upside potential than Sonic Healthcare, analysts believe Immutep is more attractive than Sonic Healthcare.
Company Buy Ratings Hold Ratings Sell Ratings SKHCFSonic Healthcare0 0 0 IMMPImmutep2 0 0 -
Is SKHCF or IMMP More Risky?
Sonic Healthcare has a beta of 1.133, which suggesting that the stock is 13.342% more volatile than S&P 500. In comparison Immutep has a beta of 2.197, suggesting its more volatile than the S&P 500 by 119.655%.
-
Which is a Better Dividend Stock SKHCF or IMMP?
Sonic Healthcare has a quarterly dividend of $0.42 per share corresponding to a yield of 4.19%. Immutep offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sonic Healthcare pays 109.44% of its earnings as a dividend. Immutep pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SKHCF or IMMP?
Sonic Healthcare quarterly revenues are --, which are smaller than Immutep quarterly revenues of --. Sonic Healthcare's net income of -- is lower than Immutep's net income of --. Notably, Sonic Healthcare's price-to-earnings ratio is 22.75x while Immutep's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sonic Healthcare is 1.36x versus -- for Immutep. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SKHCFSonic Healthcare1.36x 22.75x -- -- IMMPImmutep-- -- -- --
-
Which has Higher Returns SKHCF or KZIA?
Kazia Therapeutics has a net margin of -- compared to Sonic Healthcare's net margin of --. Sonic Healthcare's return on equity of 6.28% beat Kazia Therapeutics's return on equity of -1083.16%.
Company Gross Margin Earnings Per Share Invested Capital SKHCFSonic Healthcare-- -- $7.4B KZIAKazia Therapeutics-- -- -$6.3M -
What do Analysts Say About SKHCF or KZIA?
Sonic Healthcare has a consensus price target of --, signalling downside risk potential of --. On the other hand Kazia Therapeutics has an analysts' consensus of -- which suggests that it could grow by 1010.15%. Given that Kazia Therapeutics has higher upside potential than Sonic Healthcare, analysts believe Kazia Therapeutics is more attractive than Sonic Healthcare.
Company Buy Ratings Hold Ratings Sell Ratings SKHCFSonic Healthcare0 0 0 KZIAKazia Therapeutics0 0 0 -
Is SKHCF or KZIA More Risky?
Sonic Healthcare has a beta of 1.133, which suggesting that the stock is 13.342% more volatile than S&P 500. In comparison Kazia Therapeutics has a beta of 2.117, suggesting its more volatile than the S&P 500 by 111.748%.
-
Which is a Better Dividend Stock SKHCF or KZIA?
Sonic Healthcare has a quarterly dividend of $0.42 per share corresponding to a yield of 4.19%. Kazia Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sonic Healthcare pays 109.44% of its earnings as a dividend. Kazia Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SKHCF or KZIA?
Sonic Healthcare quarterly revenues are --, which are smaller than Kazia Therapeutics quarterly revenues of --. Sonic Healthcare's net income of -- is lower than Kazia Therapeutics's net income of --. Notably, Sonic Healthcare's price-to-earnings ratio is 22.75x while Kazia Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sonic Healthcare is 1.36x versus -- for Kazia Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SKHCFSonic Healthcare1.36x 22.75x -- -- KZIAKazia Therapeutics-- -- -- --
-
Which has Higher Returns SKHCF or MESO?
Mesoblast has a net margin of -- compared to Sonic Healthcare's net margin of --. Sonic Healthcare's return on equity of 6.28% beat Mesoblast's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SKHCFSonic Healthcare-- -- $7.4B MESOMesoblast-- -- -- -
What do Analysts Say About SKHCF or MESO?
Sonic Healthcare has a consensus price target of --, signalling downside risk potential of --. On the other hand Mesoblast has an analysts' consensus of $11.00 which suggests that it could grow by 18.67%. Given that Mesoblast has higher upside potential than Sonic Healthcare, analysts believe Mesoblast is more attractive than Sonic Healthcare.
Company Buy Ratings Hold Ratings Sell Ratings SKHCFSonic Healthcare0 0 0 MESOMesoblast1 0 0 -
Is SKHCF or MESO More Risky?
Sonic Healthcare has a beta of 1.133, which suggesting that the stock is 13.342% more volatile than S&P 500. In comparison Mesoblast has a beta of 3.357, suggesting its more volatile than the S&P 500 by 235.658%.
-
Which is a Better Dividend Stock SKHCF or MESO?
Sonic Healthcare has a quarterly dividend of $0.42 per share corresponding to a yield of 4.19%. Mesoblast offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sonic Healthcare pays 109.44% of its earnings as a dividend. Mesoblast pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SKHCF or MESO?
Sonic Healthcare quarterly revenues are --, which are smaller than Mesoblast quarterly revenues of --. Sonic Healthcare's net income of -- is lower than Mesoblast's net income of --. Notably, Sonic Healthcare's price-to-earnings ratio is 22.75x while Mesoblast's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sonic Healthcare is 1.36x versus 196.60x for Mesoblast. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SKHCFSonic Healthcare1.36x 22.75x -- -- MESOMesoblast196.60x -- -- --
-
Which has Higher Returns SKHCF or OPT?
Opthea has a net margin of -- compared to Sonic Healthcare's net margin of --. Sonic Healthcare's return on equity of 6.28% beat Opthea's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SKHCFSonic Healthcare-- -- $7.4B OPTOpthea-- -- $65.7M -
What do Analysts Say About SKHCF or OPT?
Sonic Healthcare has a consensus price target of --, signalling downside risk potential of --. On the other hand Opthea has an analysts' consensus of $11.80 which suggests that it could grow by 229.72%. Given that Opthea has higher upside potential than Sonic Healthcare, analysts believe Opthea is more attractive than Sonic Healthcare.
Company Buy Ratings Hold Ratings Sell Ratings SKHCFSonic Healthcare0 0 0 OPTOpthea4 0 0 -
Is SKHCF or OPT More Risky?
Sonic Healthcare has a beta of 1.133, which suggesting that the stock is 13.342% more volatile than S&P 500. In comparison Opthea has a beta of 0.710, suggesting its less volatile than the S&P 500 by 29.036%.
-
Which is a Better Dividend Stock SKHCF or OPT?
Sonic Healthcare has a quarterly dividend of $0.42 per share corresponding to a yield of 4.19%. Opthea offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sonic Healthcare pays 109.44% of its earnings as a dividend. Opthea pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SKHCF or OPT?
Sonic Healthcare quarterly revenues are --, which are smaller than Opthea quarterly revenues of --. Sonic Healthcare's net income of -- is lower than Opthea's net income of --. Notably, Sonic Healthcare's price-to-earnings ratio is 22.75x while Opthea's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sonic Healthcare is 1.36x versus 2,361.28x for Opthea. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SKHCFSonic Healthcare1.36x 22.75x -- -- OPTOpthea2,361.28x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will American Tower Stock Recover?
The performance of the real estate investment trust, or REIT,…
Will Booking Holdings Stock Split?
Booking Holdings, the travel and technology company that owns brands…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 21.88% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is down 6.11% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is up 0.83% over the past day.
